Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A 64-year-old woman with meningioma presented with left-sided lenticulostriatal ischemia following craniotomy and debulking of a sphenoid wing meningioma. For subsequent radiotherapy planning, an SSTR-targeted PET/CT using the novel ligand 18 F-SiTATE was performed 2.5 months thereafter. The meningioma remnants showed transosseous, intrasellar, and perivascular extension around the internal carotid artery with strong SSTR expression. Moreover, there was focal 18 F-SiTATE uptake in the left caudate and corresponding contrast enhancement due to postischemic blood-brain barrier disruption and reactive SSTR expression. Therefore, increased cortical or subcortical SSTR PET signal may be related to ischemic changes even in the subacute stage after initial stroke.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000005482 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unusual Port Site Metastasis Following Laparoscopic Resection of Ileal Neuroendocrine Tumor Evolving After a Prolonged Latency Period: 68Ga-DOTATATE PET/CT Documentation.
Clin Nucl Med
September 2025
Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Parel.
Port site metastasis is an uncommon but clinically relevant complication, particularly associated with minimally invasive surgery for abdomino-pelvic malignancies, often indicating poor prognosis and necessitating prompt evaluation for potential surgical intervention. Proposed mechanisms include direct tumor implantation, aerosolization during pneumoperitoneum, surgical wound contamination, and immune alterations. In this report, we describe a case of a 48-year-old man who developed SSTR-expressing port site metastases, occurring 4 years and 4 months following laparoscopic resection of an ileal neuroendocrine tumor (NET).
View Article and Find Full Text PDFTreatment with radionuclide-labeled peptides in refractory meningiomas: updated review and clinical perspectives.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
September 2025
Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, Córdoba, Spain.
The use of theragnostics in nuclear medicine has significantly advanced, particularly peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Meningiomas often overexpress somatostatin receptors (SSTR), making them potential candidates for PRRT. However, the lack of large-scale standardized trials limits its clinical application.
View Article and Find Full Text PDFCharacterization of Sinonasal Lesions on CT, MRI, and PET/CT.
Clin Nucl Med
September 2025
Department of Radiology, Division of Neuroradiology, University of Miami Miller School of Medicine, Jackson Memorial Hospital, Miami, FL.
The differential diagnosis of sinonasal lesions includes benign and malignant disease. Current radiologic diagnosis depends on the complementary roles of CT and MRI. PET/CT has been widely utilized for diagnosis and staging of various types of tumors as well as assessing treatment response.
View Article and Find Full Text PDFThe neuroendocrine regulation of hepatic cytochrome P450 by N-methyl-D-aspartate receptors in the paraventricular and arcuate nuclei of the hypothalamus.
Drug Metab Dispos
August 2025
Department of Pharmacokinetics and Drug Metabolism, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland. Electronic address:
Our previous study showed that the antagonist of the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor, the compound CP-101,606, negatively affected hepatic cytochrome P450 (P450) expression and activity after intraperitoneal administration. The aim of our current study was to demonstrate the effect of intracerebral administration of CP-101,606 into the paraventricular (PVN) or arcuate (ARC) nuclei of the hypothalamus on the central neuroendocrine regulation of P450. Male rats received bilateral injections of CP-101,606 into the PVN or ARC for 5 days.
View Article and Find Full Text PDFSurvival Outcome for Peptide Receptor Radionuclide Therapy in Olfactory Neuroblastoma.
Anticancer Res
September 2025
Department of Head and Neck Surgery, Aichi Cancer Center, Nagoya, Japan.
Background/aim: Systemic therapy for olfactory neuroblastoma with unresectable multi-recurrence disease is unestablished. However, peptide receptor radionuclide therapy (PRRT) with 177Lu-pentetreotide is considered to be an effective systemic treatment for unresectable multi-recurrence olfactory neuroblastoma expressing somatostatin receptors. This study investigated the association between survival outcome and treatment modality in olfactory neuroblastoma, with a focus on peptide receptor radionuclide therapy.
View Article and Find Full Text PDF